Resources

Generation of scalable off-the-shelf iNKT therapies with Synecta T1

Synecta T1 and Flowfect® Enhance Non-Viral Engineering Efficiency and Manufacturing Scalability of CD19-Directed CAR-T Cells For Hematologic Malignancies

Synecta T1 Enables Accelerated, Potent T Cell Expansion For Scalable Adoptive Immunotherapy Manufacturing

Cytiva’s Fast Trak™ (services for process development and training) evaluated Synecta T1 across both small- and large-scale expansion systems to benchmark performance against a conventional activation reagent to assess fold expansion, viability, and scalability in T-cell manufacturing workflows.

Improved T-cell Expansion, Viability, and Metabolic Fitness with Synecta Cell-Derived Nanoparticles Across Clinically-Relevant Media Conditions

Evaluation of huCART19-IL18 Manufactured Using Synecta CDNP Technology to Improve CAR-T Yield and Consistency in Cohort D of an Ongoing Phase I Study (NCT04684563)